SCHEMBL6601709

SCHEMBL6601709

O[C@H](c1ccc(F)cc1)c1nc(-c2ccc(F)cc2)c(-c2ccncc2)[nH]1

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPK14 Q16539 13/20 0.60
MAPK13 O15264 11/20 0.60
MAPK12 P53778 11/20 0.60
MAPK11 Q15759 11/20 0.60
GCGR P47871 10/20 0.60
CSNK1D P48730 3/20 0.59
PRKD3 O94806 2/20 0.59
MAP4K4 O95819 2/20 0.59
FRK P42685 2/20 0.59
MAPK9 P45984 2/20 0.59
CSNK1A1 P48729 2/20 0.59
GSK3B P49841 2/20 0.59
PTK6 Q13882 2/20 0.59
CLK4 Q9HAZ1 2/20 0.59
PRKD2 Q9BZL6 1/20 0.59
ALOX5 P09917 3/20 0.56
BRAF P15056 2/20 0.56
CSNK1E P49674 2/20 0.56
KDM4E B2RXH2 1/20 0.56
CIT O14578 1/20 0.56

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8113784 1.00 MAPK14 (0.60) MAPK14MAPK13MAPK12MAPK11GCGR
SCHEMBL4473119 0.82 MAPK14 (0.65) MAPK14MAPK13MAPK12MAPK11GCGR
SCHEMBL1387734 0.82 MAPK14 (0.67) MAPK14MAPK13MAPK12MAPK11GCGR
SCHEMBL9646788 0.82 MAPK14 (0.67) MAPK14MAPK13MAPK12MAPK11GCGR
SCHEMBL8486608 0.79 MAPK14 (0.62) MAPK14MAPK13MAPK12MAPK11GCGR
SCHEMBL5767827 0.78 MAPK14 (0.60) MAPK14MAPK13MAPK12MAPK11GCGR
SCHEMBL4919226 0.78 MAPK14 (0.58) MAPK14MAPK13MAPK12MAPK11GCGR
SCHEMBL7231228 0.78 MAPK11 (0.81) MAPK14MAPK13MAPK12MAPK11GCGR
SCHEMBL8137635 0.78 MAPK14 (0.55) MAPK14MAPK13MAPK12MAPK11GCGR
SCHEMBL6107665 0.76 MAPK14 (0.54) MAPK14MAPK13MAPK12MAPK11GCGR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1396491-A2 2-substituted 4,5-diaryl-imidazoles and their use as p38 MAP kinase inhibitors Novartis AG (CH) 2004-03-10 EP claimed
EP-1396491-A2 2-substituted 4,5-diaryl-imidazoles and their use as p38 MAP kinase inhibitors Novartis AG (CH) 2004-03-10 EP disclosed
US-6300347-B1 FOR THERAPY OF TUMOR NECROSIS FACTOR AND INTERLEUKIN-1 MEDIATED DISEASES SUCH AS RHEUMATOID ARTHRITIS AND DISEASES OF BONE METABOLISM, E.G. OSTEOPOROSIS NOVARTIS AG (CH) 2001-10-09 US disclosed